Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OCUL
OCUL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OCUL News
Ocular Therapeutix Reports Q4 Earnings with Revenue Decline
Feb 05 2026
seekingalpha
Sanofi Prepares to Raise Bid for Ocular Therapeutix to $16 per Share
Jan 15 2026
Benzinga
Boston Scientific Acquires Penumbra at $374 per Share
Jan 15 2026
Benzinga
Sanofi Prepares Enhanced Takeover Bid for Ocular Therapeutix, Shares Surge 21%
Jan 15 2026
seekingalpha
Ocular Therapeutics (OCUL) Shares Surge 23% on Positive Late-Stage Pipeline Developments
Jan 15 2026
NASDAQ.COM
Ocular Therapeutix Rejects Sanofi's Bid, Stock Surges 13%
Jan 15 2026
stocktwits
OCUL Stock Fluctuations: 52-Week Low at $5.785, High at $16.44
Jan 12 2026
NASDAQ.COM
IHE ETF Shows 9.94% Upside Potential Based on Analyst Targets
Jan 05 2026
NASDAQ.COM
Noteworthy OCUL Put and Call Options Set for February 2026
Dec 19 2025
NASDAQ.COM
Ocular Therapeutix Accelerates FDA Submission for Wet AMD Treatment
Dec 08 2025
Newsfilter
Ocular Therapeutix Shares Surge Following Accelerated FDA Approval Process for Vision Medication
Dec 08 2025
Benzinga
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Ocular Plans to Submit NDA for AXPAXLI in Wet AMD Following Positive SOL-1 Data
Dec 08 2025
Globenewswire
Ocular Plans to Submit NDA for AXPAXLI in Wet AMD Following Positive SOL-1 Data
Dec 08 2025
Newsfilter
Confluent Shares Surge Nearly 32%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 08 2025
Benzinga
Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains
Dec 08 2025
NASDAQ.COM
Show More News
